Market Cap (In CNY)
11 Billion
Revenue (In CNY)
431.38 Million
Net Income (In CNY)
-513.87 Million
Avg. Volume
15.8 Million
- Currency
- CNY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8.83-14.95
- PE
- -
- EPS
- -
- Beta Value
- 0.699
- ISIN
- CNE1000011T7
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Honghong Tu
- Employee Count
- -
- Website
- https://www.hybio.com.cn
- Ipo Date
- 2011-04-07
- Details
- Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.
More Stocks
-
CINGCingulate Inc.
CING
-
SUH
-
9562
-
DHB
-
FMCCJ
-
CXDOCrexendo, Inc.
CXDO
-
MRM
-
KRG